logo

For the Inventor, By the Inventor

New York, NY, United States of America

Intercept Pharmaceuticals, Inc.


USPTO Granted Patents = 62

% Expired Patents = 25.8



Trademarks = 8

Forward Citations = 265

Loading Chart...
Loading Chart...

61 inventors (with patents filed for the assignee):

goldMedal Roberto Pellicciari (40 out of 66 patents)

silverMedal Mark Pruzanski (15 out of 15 patents)

bronzeMedal Antimo Gioiello (10 out of 10 patents)

4.  Stefano Fiorucci (8 out of 16 patents)

5.  Emma Sharp (6 out of 11 patents)

6.  Alex Eberlin (6 out of 21 patents)

7.  André Steiner (6 out of 6 patents)

8.  Emilie Jolibois (6 out of 6 patents)

9.  Heidi Waenerlund Poulsen (6 out of 6 patents)

10.  Melissa Rewolinski (6 out of 7 patents)

11.  Ralf Gross (6 out of 6 patents)

12.  Fiona Dubas-Fisher (6 out of 6 patents)

13.  Mitsuhiro Matono (5 out of 8 patents)

14.  Kay Olmstead (4 out of 19 patents)

15.  Gabriel Galvin (4 out of 7 patents)


Core Competencies:
Bile Acid Derivatives
Farnesoid X Receptor
TGR5 Modulators
Obeticholic Acid
Combination Therapy
Cancer Treatment
Fibrosis
Steroid Agonists
Pharmaceutical Compositions
Hepatic Regeneration
Isotopically Labeled Compounds
3-Desoxy Derivative

62 patents:

1. 12337003 - Pharmaceutical compositions for combination therapy (2025-06-24),
2. 12291549 - Farnesoid X receptor modulators (2025-05-06),
3. 11807659 - TGR5 modulators and methods of use thereof (2023-11-07),
4. 11472831 - Isotopically labeled bile acid derivatives (2022-10-18),
5. 11419878 - Medicine obtained by combining FXR agonist and ARB (2022-08-23),
6. 11413295 - Oral preparation of obeticholic acid (2022-08-16),
7. 11345721 - TGR5 modulators and methods of use thereof (2022-05-31),
8. 11319337 - 3-desoxy derivative and pharmaceutical compositions thereof (2022-05-03),
9. 11311557 - Pharmaceutical compositions for combination therapy (2022-04-26),
10. 11072631 - Methods and intermediates for the preparation bile acid derivatives (2021-07-27),
11. 11066437 - Methods and intermediates for the preparation of bile acid derivatives (2021-07-20),
12. 11034717 - Farnesoid X receptor modulators (2021-06-15),
13. 11000532 - Farnesoid x receptor modulators (2021-05-11),
14. 10987362 - Treatment of fibrosis using FXR ligands (2021-04-27),
15. 10894054 - FXR agonist compositions for combination therapy (2021-01-19),
Intercept Pharmaceuticals, Inc., based in New York, NY, specializes in the development of innovative therapies targeting liver diseases. The company focuses on bile acid modulators, particularly through its core technology involving bile acid derivatives and the Farnesoid X receptor. Intercept's research encompasses various therapeutic areas, including fibrosis and cancer treatment, utilizing compounds such as obeticholic acid and TGR5 modulators. Their commitment to advancing combination therapies positions them at the forefront of addressing complex liver conditions.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Intercept Pharmaceuticals, Inc.
62 Patents

#160 in New York, NY

#348 in New York

#5,842 in US

#11,761 in the World

New York, NY (US)
New York, NY, United States of America

Intercept Pharmaceuticals, Inc.

Forward Citations = 265

61 inventors:

goldMedal Roberto Pellicciari (40 out of 66 patents)

silverMedal Mark Pruzanski (15 out of 15 patents)

bronzeMedal Antimo Gioiello (10 out of 10 patents)

4.  Stefano Fiorucci (8 out of 16 patents)

5.  Emma Sharp (6 out of 11 patents)

Please report any incorrect information to [email protected]
Loading…